Background: Carica papaya is a tropical herb used traditionally for multiple medicinal uses. Its phytochemical compounds, like flavonoids and alkaloids, are antioxidant and anti-inflammatory in nature. The existing evidence indicates its possible involvement in cardiovascular health, especially in the control of hypertension. The objective of the current commentary is to highlight the dual therapeutic significance of C. papaya in the prevention and management of inflammation and hypertension.
Methods: This narrative review summarizes preclinical and clinical research on C. papaya. A targeted literature search (2000–2024) identified seven relevant studies on C. papaya in relation to hypertension and inflammation, which were included to support this commentary. Information was gathered from PubMed, Scopus, and Google Scholar, highlighting its antihypertensive and anti-inflammatory activity. Underlying mechanisms, such as antioxidant modulation and Angiotensin-converting enzyme (ACE) inhibition, were examined critically.
Results: Research indicates that C. papaya extracts decrease inflammatory markers and enhance vascular function. Animal models exhibit marked decreases in blood pressure and oxidative stress levels. The reported beneficial effects demonstrated that papaya may exert these effects through multiple mechanisms, such as the modulation of inflammatory pathways, augmentation of antioxidant defence, and direct vasodilation. Limited clinical trials have indicated favorable results, which justify further research.
Conclusion: C. papaya is a promising natural adjunct to inflammation and hypertension management. Its phytochemical complexity underlies its therapeutic effects through several mechanisms. Human studies are required to establish its efficacy and standardized dosing.